X4 PHARMACEUTICALS, INC.
61 North Beacon Street, 4th Floor
Boston, MA 02134
October 22, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Ada D. Sarmento |
| RE: | X4 Pharmaceuticals, Inc. |
Registration Statement on Form S-3
File No. 333-249544
Acceleration Request
Requested Date: October 26, 2020
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-249544) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Monday, October 26, 2020, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722 or with Courtney T. Thorne of Cooley LLP at (617) 937-2318.
[Signature page follows]
| Sincerely,
X4 PHARMACEUTICALS, INC. | ||
| By: | /s/ Adam S. Mostafa | |
| Adam S. Mostafa Chief Financial Officer | ||
| cc: | Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc. |
Daniel I. Goldberg, Cooley LLP
Courtney T. Thorne, Cooley LLP